Raymond James Financial
CHRS icon

Raymond James Financial’s Coherus Oncology CHRS Stock Holding History

Raymond James Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,102
Closed -$2.27K – 5286
2025
Q2 		$2.27K Buy
+3,102
New +$2.68K ﹤0.01% 6383

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Raymond James Financial's CHRS Position: Q3 2025 in Review

Raymond James Financial sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 3,102 shares — an estimated $2.27K sold.

Raymond James Financial first reported a position in CHRS in Q2 2025 and held it in 1 quarter. The position peaked at $2.27K in Q2 2025. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Raymond James Financial reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 3,102 Coherus Oncology shares in Q3 2025, an estimated $2.27K.
  • Raymond James Financial first reported a position in Coherus Oncology in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Coherus Oncology position peaked at $2.27K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.